Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

News In Brief

This article was originally published in The Gray Sheet

Executive Summary

Obama signs appropriations bill giving FDA expanded user fee access. Bausch & Lomb IPO. More news.

You may also be interested in...



Court Grants Covidien Injunction Over Ethicon Endo-Surgery’s Surgical Shears

Covidien argues that despite a previous court ruling under appeal that Ethicon infringed on several of Covidien’s patents, the company has continued to use those designs in their line of Harmonic Ace surgical products.

News Briefs: Invacare Update; Patent Trolls; VC Trends

Invacare reports its earnings are hindered by an FDA consent decree, but management hopes to be released from the agreement soon. The American Hospital Association signs onto a letter to Congress calling for a crackdown on so-called “patent trolls.” More news in brief

News In Brief

Senate symbolically votes to repeal device tax. Sequester will take about 5 percent from device user fees. More news in brief.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT031928

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel